Prognostic role of neutrophil-lymphocyte and platelet-lymphocyte ratio in pancreatic cancer

Abstract

vs R1 in 1 and 5 years survival).Prognostic factors were determining the type and origin of the tumor, as well as tumor size (<2 cm longer survival).

Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios inversely correlate to clinical and pathologic stage in patients with resectable pancreatic ductal adenocarcinoma

“…It is worth noting that previous authors acknowledged the limitations of their meta-analyses and weakness due to intrinsic heterogeneity, including but not limited to small sample size, variability in cut off levels used, variation in demographic patient population, difference in interventions, large spectrum of clinical stage included, endpoint criteria, and retrospective nature of study (10,26). Most importantly there is a recognized publication bias due to inclusion of studies with positive results and possible exclusion of non-published negative results (29,30) Therefore, we urge caution when evaluating both (NLR and PLR) novel biomarkers from our retrospective review of resectable pancreatic adenocarcinoma patients in order to avoid potential controversy.…”

Preoperative platelet lymphocyte ratio as independent predictors of prognosis in pancreatic cancer: A systematic review and meta-analysis

“…Recently, the preoperative platelet to lymphocyte ratio (PLR), which also reflects the degree of systemic inflammation, has been found to be linked to prognosis in patients with PC [ 7 – 9 ]. However, some studies failed to find correlation between PLR and prognosis of PC [ 10 – 12 ]. We therefore conducted a meta-analysis to assess the prognostic effect of preoperative PLR in PC.…”